Header Logo

Connection

Lynn Morris to HIV Envelope Protein gp41

This is a "connection" page, showing publications Lynn Morris has written about HIV Envelope Protein gp41.
Connection Strength

2,416
  1. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532.
    View in: PubMed
    Score: 0,382
  2. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol. 2009 Nov; 83(21):11265-74.
    View in: PubMed
    Score: 0,330
  3. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):776-83.
    View in: PubMed
    Score: 0,251
  4. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004 May; 20(5):477-82.
    View in: PubMed
    Score: 0,228
  5. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
    View in: PubMed
    Score: 0,170
  6. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,138
  7. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207.
    View in: PubMed
    Score: 0,134
  8. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61.
    View in: PubMed
    Score: 0,118
  9. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26.
    View in: PubMed
    Score: 0,117
  10. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226.
    View in: PubMed
    Score: 0,116
  11. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011 Nov; 85(21):11502-19.
    View in: PubMed
    Score: 0,095
  12. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63.
    View in: PubMed
    Score: 0,078
  13. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
    View in: PubMed
    Score: 0,073
  14. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006 Mar; 80(5):2515-28.
    View in: PubMed
    Score: 0,065
  15. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
    View in: PubMed
    Score: 0,051
  16. Coreceptor usage and biological phenotypes of HIV-1 isolates. Clin Chem Lab Med. 2002 Sep; 40(9):911-7.
    View in: PubMed
    Score: 0,051
  17. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68.
    View in: PubMed
    Score: 0,019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.